Kopran Limited (KOPRAN) shares Q2 2026-27 financial results, highlighting revenue growth and operational performance.
Sai Parenterals Limited (SAIPARENT) Q2 FY27 results show revenue up 9% QoQ, PAT grows 32.7% QoQ, ahead of FY27 targets.
CORONA Remedies Limited (CORONA) reports highest ever revenue with 22% growth for Q2FY27 on Y-o-Y basis, outperforming IPM.
Sanofi India Limited's board meeting concluded at 4:45 p.m. on October 29, 2026, with significant focus on strategic initiatives.
Senores Pharmaceuticals Limited (SENORES) reports Q2 FY27 revenue up 25% and EBITDA +38%, driven by strong performance across markets.
CORONA Remedies Limited (CORONA) receives ANVISA GMP certification for Bhayla manufacturing, reinforcing its commitment to 'One World, One Quality'.
Kopran Limited (KOPRAN) announces successful EU Medicine Authority GMP inspection at Khopoli facility, with no critical observations.
